| 发明名称 | Methods involving PDGFRBETA inhibitors | ||
| 摘要 | The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL. | ||
| 申请公布号 | US8933037(B2) | 申请公布日期 | 2015.01.13 |
| 申请号 | US201013498827 | 申请日期 | 2010.09.28 |
| 申请人 | Medizinische Universitat Wien | 发明人 | Kenner Lukas;Laimer Daniela |
| 分类号 | A61P35/00;A61K31/506;A61K31/404;A61K31/4439;A61K45/06 | 主分类号 | A61P35/00 |
| 代理机构 | Fulbright & Jaworski LLP | 代理人 | Fulbright & Jaworski LLP |
| 主权项 | 1. A method of treating a patient with anaplastic lymphoma kinase+(ALK+)-anaplastic large cell lymphoma (ALCL) and susceptible to a cell proliferative disorder comprising: obtaining a platelent-derived growth factor receptor beta (PDGFRbeta) antagonist; and administering the PDGFRbeta antagonist to the patient. | ||
| 地址 | Vienna AT | ||